Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma

Denitsa Koynova, Ekaterina Jordanova, Nicole Kukutsch, Pieter Van Der Velden, Draga Toncheva, Nelleke Gruis*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: In order to obtain better insight into the genetic background of nodular melanoma (NM), we aimed to analyse the frequency of CDKN2A and C-MYC copy number changes. The impact of these aberrations on the metastatic potential and patient's survival was considered. Methods: Fluorescent in situ hybridization was used to analyse the C-MYC and CDKN2A genes on isolated nuclei from 49 paraffin-embedded primary NMs. Results: Thirty-six (73.47%) melanoma samples showed CDKN2A deletion while 11 of these 36 (22.45%) additionally displayed C-MYC increased copy numbers. Cases positive for metastases more commonly displayed CDKN2A deletions. However, the combined C-MYC and CDKN2A aberrations were found predominantly in the non-metastasizing group of primary NM. The survival analysis furthermore demonstrated that patients with combined CDKN2A and C-MYC aberrations have a significantly better prognosis than carriers of CDKN2A deletion only. Conclusions: We conclude that the C-MYC increased copy number changes on the background of CDKN2A deletions seem to be related to a low metastatic potential and better patients' outcome in primary NMs.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume133
Issue number2
DOIs
Publication statusPublished - Feb 2007

Cite this